Cancer drug developer Oric Pharmaceuticals (NASDAQ:ORIC) successfully raised $120 million in its IPO on Friday, and the stock posted a splashy opening-day gain of 61%. Here are a few reasons why this company was so appealing to investors, even during this time of crisis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,